Results 91 to 100 of about 8,597,475 (170)

Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration

, 2015
Arshad M Khanani Sierra Eye Associates, Reno, NV, USA Purpose: To evaluate the durability of fixed bimonthly dosing of intravitreal aflibercept for neovascular age-related macular degeneration.Methods: Records of 16 patients were retrospectively ...
Khanani AM
core  

Early real-world outcomes of intravitreal aflibercept 8 mg in treatment-Naïve neovascular AMD: AI-assisted fluid volume analysis.

This study was conducted as a retrospective, exploratory analysis to assess early anatomical and functional effects of intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (nAMD) in a small cohort of patients.
Montesel, A., De Oliveira Figueiredo, E.C., Cattaneo, J., Vermeirsch, S., Eandi, C.M.   +4 more
core   +1 more source

Non-infectious occlusive retinal vasculitis following switching from aflibercept 2 mg to aflibercept 8 mg in neovascular age-related macular degeneration: a real-world case report

Abstract Background Anti–vascular endothelial growth factor (anti-VEGF) therapy represents the standard of care for neovascular age-related macular degeneration (nAMD). Aflibercept 8 mg was recently introduced with extended dosing intervals and favorable safety outcomes in phase III trials.
Ermal Simaku, Ahmed Nour Eddien, Megi Popa, Ahmed El Shafei   +3 more
openaire   +1 more source

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion

, 2016
Remya Paulose,1 Jay Chhablani,1 Chintan J Dedhia,1 Michael W Stewart,2 Ahmad M Mansour3,4 1Smt. Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India; 2Department of Ophthalmology, Mayo Clinic, Jacksonville, FL ...
Paulose R, Dedhia CJ, Chhablani J, Mansour AM, Stewart MW   +4 more
core  

Short-Term Outcomes of Three Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative Age-Related Macular Degeneration

Background/Objectives: The aim was to investigate the short-term outcomes of three consecutive monthly aflibercept 8 mg administrations for treatment-naïve eyes with exudative age-related macular degeneration (AMD).
Yoichi Sakurada, Yumi Kotoda, Wataru Kikushima, Shuhei Hosoda, Kenji Kashiwagi, Yoshiko Fukuda   +5 more
core   +1 more source

Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study

, 2016
Andrii R Korol, Oleg S Zadorozhnyy, Volodymyr O Naumenko, Taras B Kustryn, Nataliya V Pasyechnikova The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine, Odessa, Ukraine Purpose: To determine ...
Pasyechnikova NV, Korol AR, Zadorozhnyy OS, Kustryn TB, Naumenko VO   +4 more
core  

Effect of key baseline disease characteristics on aflibercept 8 mg dosing interval extension: A post hoc 96-week analysis of PULSAR.

Objective Post hoc analysis of the PULSAR Phase 3 trial (NCT04423718) to describe whether dosing interval outcomes were associated with key baseline disease characteristics. Design Exploratory post hoc analysis of PULSAR, a 96-week, double-masked, active-
Zhang, Xin, Stahl, Andreas, Garweg, Justus G., Munk, Marion R., Machewitz, Tobias, Leal, Sergio, Zarranz-Ventura, Javier, Chaudhary, Varun, Lanzetta, Paolo   +8 more
core   +1 more source

Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice

, 2018
Rafael Campos Polo, Consuelo Rubio Sánchez, Diego Manuel García Guisado, María José Díaz Luque Unit of Retina, Department of Ophthalmology, Hospital Virgen del Puerto, Plasencia, Cáceres, Spain Purpose: To ...
Rubio Sánchez C, Garcia Guisado DM, Campos Polo R, Díaz Luque MJ   +3 more
core  

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema

Ophthalmology
Diana V. Do, Charles C. Wykoff, Sobha Sivaprasad, David M. Brown, David S. Boyer, Taiji Sakamoto, Peter Win, Sunir Joshi, Hani Salehi-Had, András Seres, Alyson J. Berliner, Sergio Leal, Robert Vitti, Karen W. Chu, Kimberly Reed, Yenchieh Cheng, Rafia Bhore, Zhanying Bai, Ursula Schmidt-Ott, Thomas Schmelter, Andrea Schulze, Zoran Hasanbasic, Peter J. Morgan-Warren, Xin Zhang, Boaz Hirshberg, George D. Yancopoulos   +25 more
openaire   +1 more source

Short-term intraocular pressure changes following intravitreal injections of aflibercept 8mg versus 2mg: A prospective comparative study

Purpose The increased injection volume of aflibercept 8 mg (0.07 ml versus 0.05 ml) raises theoretical concerns regarding intraocular pressure (IOP) effects.
Hamza Nawaz, Saleh Sahbi, Imran Karim Janmohamed, Anibe Ata, Arsam Mahmood, Haasher Monib, Shabeeba Hannan, Luke Membrey   +7 more
core   +1 more source